PRODYGY is a Phase I/II study to assess the safety, tolerability, efficacy and quality of life following a single subretinal injection of SPVN06 in the worst-seeing eye of adult patients with RP due t...
Read more
SpliceBio, compañía biotecnológica de terapia génica con sede en Barcelona basada en tecnología desarrollada en la Universidad de Princeton, ha recibido el galardón a la “Ronda de Inversión S...
Read more
The AXESS European pivotal trial is a prospective, single arm study to evaluate the safety and performance of aXess in patients with end-stage renal disease who need hemodialysis.
Read more
The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
Read more
Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading E...
Read more
Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported...
Read more
Galecto, Inc., a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline d...
Read more
New innovations, like AELIX’ T-cell vaccine, leading to a prolonged period without ART, could be a gamechanger in HIV cure strategies as a combination approach to treating the disease.
Read more
Clear path forward for ilofotase alfa as potential treatment in acute kidney injury, based on consistent improvement of renal parameters observed in REVIVAL and other clinical studies
Read more
Xeltis, a medtech company developing the most advanced polymer-based restorative cardiovascular devices, today announced very promising preliminary efficacy and safety results from one of the centers ...
Read more
Aura Biosciences today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Inv...
Read more
Galecto today announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The research helps understand the biological basis of a rare neurodeve...
